Area of research
Oncology · Cancer Research
Research interest
Research focused on Response Evaluation Criteria in Solid Tumors and Adverse effect, with related work in Clinical endpoint, Gemcitabine, KRAS. Notable publications include 'Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded,...', 'Abstract CT030: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study', and 'A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice'.
Safety of fruquintinib monotherapy and combination therapy in Chinese patients with colorectal cancer in real-world clinical practice: A subgroup analysis from phase IV study.
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice
Abstract CT030: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study
Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer
A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.
Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.